Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 95 results for schizophrenia

  1. Past appeals and decisions

    TA037 Rituximab for follicular lymphoma 21 May 2001 TA043 Schizophrenia - Atypical antipsychotic 24 April 2002 TA397 Systemic lupus...

  2. Learning disability: identifying and managing mental health problems (QS142)

    This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.

    Quality standard
    Published
    10 January 2017
    View quality statements

    Sections for QS142

  3. What is the impact of coexisting physical health conditions on the mortality of people with complex psychosis?

    antipsychotic medicines recommended in the NICE guidelines on psychosis and schizophrenia in adults and bipolar disorder should form the...

    Research recommendation
    Published
    26 October 2020

  4. What is the clinical and cost effectiveness of omega-3 fatty acids in the treatment of children and young people considered to be at high risk of developing psychosis?

    Source guidance details Comes from guidance Psychosis and schizophrenia in children and young people: recognition and management Number

    Research recommendation
    Published
    9 June 2015

  5. What is the clinical and cost effectiveness for family intervention combined with individual CBT in the treatment of children and young people considered to be at high risk of developing psychosis and their parents or carers?

    Source guidance details Comes from guidance Psychosis and schizophrenia in children and young people: recognition and management Number

    Research recommendation
    Published
    9 June 2015

  6. Maintaining the benefits of early intervention in psychosis services after discharge:- How can the benefits of early intervention in psychosis services be maintained once service users are discharged after 3 years?

    Source guidance details Comes from guidance Psychosis and schizophrenia in adults: prevention and management Number CG178 Date

    Research recommendation
    Published
    9 June 2015

  7. The physical health benefits of discontinuing antipsychotic medication:- What are the short- and long-term benefits to physical health of guided medication discontinuation and/or reduction in first episode psychosis and can this be achieved without major risks?

    Source guidance details Comes from guidance Psychosis and schizophrenia in adults: prevention and management Number CG178 Date

    Research recommendation
    Published
    9 June 2015

  8. Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)

    This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.

    Clinical guideline
    Last updated
    20 December 2017
    View recommendations

    Sections for CG128

  9. What are the long-term outcomes, both psychotic and nonpsychotic, for children and young people with attenuated or transient psychotic symptoms suggestive of a developing psychosis, and can the criteria for 'at risk states' be refined to better predict those who will and those who will not go on to develop psychosis?

    Source guidance details Comes from guidance Psychosis and schizophrenia in children and young people: recognition and management Number

    Research recommendation
    Published
    9 June 2015

  10. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication (HTE10)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication....

    Health technology evaluation
    Published
    26 September 2023
    View recommendations

    Sections for HTE10

  11. Committee D members

    Find out more about NICE technology appraisals advisory committee D members

  12. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

    Evidence-based recommendations on aripiprazole for treating moderate to severe manic episodes in young people with bipolar I disorder.

    Technology appraisal guidance
    Published
    24 July 2013
    View recommendations

    Sections for TA292

  13. Schizophrenia (CG1)

    This guidance has been updated and replaced by NICE guideline CG82.

    Clinical guideline
    Published
    1 December 2002

  14. Mental health problems in people with learning disabilities: prevention, assessment and management (NG54)

    This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.

    NICE guideline
    Published
    14 September 2016
    View recommendations

    Sections for NG54

  15. Schizophrenia: lurasidone (ESNM15)

    This evidence summary has been replaced by ESNM48

    Evidence summary
    Published
    9 April 2013